<DOC>
	<DOC>NCT02687828</DOC>
	<brief_summary>This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal Behcet's disease (BD) patients in routine clinical practice.</brief_summary>
	<brief_title>A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients</brief_title>
	<detailed_description />
	<mesh_term>Behcet Syndrome</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subjects must be an adult &gt;= 19 years Subjects who are eligible to be treated with adalimumab for intestinal Behcet's disease in accordance with the approved label in Korea Subjects provide written authorization form for use/disclose of personal health data prior to participating in this study Subjects who are contraindicated to any antiTNF agent Female subjects who are pregnant or breast feeding Subjects who are participating in other interventional clinical trials</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>AMORE study</keyword>
	<keyword>Intestinal Behcet's disease (BD)</keyword>
</DOC>